Vimentin is a novel AKT1 target mediating motility and invasion

Q. S. Zhu, K. Rosenblatt, Kai-Lieh Huang, G. Lahat, R. Brobey, S. Bolshakov, T. Nguyen, Z. Ding, R. Belousov, K. Bill, X. Luo, A. Lazar, A. Dicker, G. B. Mills, M. C. Hung, D. Lev

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.

Original languageEnglish (US)
Pages (from-to)457-470
Number of pages14
JournalOncogene
Volume30
Issue number4
DOIs
StatePublished - Jan 27 2011
Externally publishedYes

Fingerprint

Vimentin
Sarcoma
Neoplasms
Cell Movement
Phosphorylation
Neoplasm Metastasis
Intermediate Filaments
Growth
Caspases
Metabolic Networks and Pathways
Phosphatidylinositol 3-Kinases
Proteolysis
Protein Isoforms
Head

Keywords

  • AKT1
  • migration/invasion
  • phosphorylation
  • soft-tissue sarcoma
  • vimentin

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Zhu, Q. S., Rosenblatt, K., Huang, K-L., Lahat, G., Brobey, R., Bolshakov, S., ... Lev, D. (2011). Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene, 30(4), 457-470. https://doi.org/10.1038/onc.2010.421

Vimentin is a novel AKT1 target mediating motility and invasion. / Zhu, Q. S.; Rosenblatt, K.; Huang, Kai-Lieh; Lahat, G.; Brobey, R.; Bolshakov, S.; Nguyen, T.; Ding, Z.; Belousov, R.; Bill, K.; Luo, X.; Lazar, A.; Dicker, A.; Mills, G. B.; Hung, M. C.; Lev, D.

In: Oncogene, Vol. 30, No. 4, 27.01.2011, p. 457-470.

Research output: Contribution to journalArticle

Zhu, QS, Rosenblatt, K, Huang, K-L, Lahat, G, Brobey, R, Bolshakov, S, Nguyen, T, Ding, Z, Belousov, R, Bill, K, Luo, X, Lazar, A, Dicker, A, Mills, GB, Hung, MC & Lev, D 2011, 'Vimentin is a novel AKT1 target mediating motility and invasion', Oncogene, vol. 30, no. 4, pp. 457-470. https://doi.org/10.1038/onc.2010.421
Zhu QS, Rosenblatt K, Huang K-L, Lahat G, Brobey R, Bolshakov S et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011 Jan 27;30(4):457-470. https://doi.org/10.1038/onc.2010.421
Zhu, Q. S. ; Rosenblatt, K. ; Huang, Kai-Lieh ; Lahat, G. ; Brobey, R. ; Bolshakov, S. ; Nguyen, T. ; Ding, Z. ; Belousov, R. ; Bill, K. ; Luo, X. ; Lazar, A. ; Dicker, A. ; Mills, G. B. ; Hung, M. C. ; Lev, D. / Vimentin is a novel AKT1 target mediating motility and invasion. In: Oncogene. 2011 ; Vol. 30, No. 4. pp. 457-470.
@article{f87933f6c9d747ba82ca87c6e6143918,
title = "Vimentin is a novel AKT1 target mediating motility and invasion",
abstract = "The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.",
keywords = "AKT1, migration/invasion, phosphorylation, soft-tissue sarcoma, vimentin",
author = "Zhu, {Q. S.} and K. Rosenblatt and Kai-Lieh Huang and G. Lahat and R. Brobey and S. Bolshakov and T. Nguyen and Z. Ding and R. Belousov and K. Bill and X. Luo and A. Lazar and A. Dicker and Mills, {G. B.} and Hung, {M. C.} and D. Lev",
year = "2011",
month = "1",
day = "27",
doi = "10.1038/onc.2010.421",
language = "English (US)",
volume = "30",
pages = "457--470",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Vimentin is a novel AKT1 target mediating motility and invasion

AU - Zhu, Q. S.

AU - Rosenblatt, K.

AU - Huang, Kai-Lieh

AU - Lahat, G.

AU - Brobey, R.

AU - Bolshakov, S.

AU - Nguyen, T.

AU - Ding, Z.

AU - Belousov, R.

AU - Bill, K.

AU - Luo, X.

AU - Lazar, A.

AU - Dicker, A.

AU - Mills, G. B.

AU - Hung, M. C.

AU - Lev, D.

PY - 2011/1/27

Y1 - 2011/1/27

N2 - The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.

AB - The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.

KW - AKT1

KW - migration/invasion

KW - phosphorylation

KW - soft-tissue sarcoma

KW - vimentin

UR - http://www.scopus.com/inward/record.url?scp=79251648304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251648304&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.421

DO - 10.1038/onc.2010.421

M3 - Article

VL - 30

SP - 457

EP - 470

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 4

ER -